{"id":"https://openalex.org/W4289776335","doi":"https://doi.org/10.33590/emjrheumatol/10311746","title":"Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge","display_name":"Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge","publication_year":2018,"publication_date":"2018-07-31","ids":{"openalex":"https://openalex.org/W4289776335","doi":"https://doi.org/10.33590/emjrheumatol/10311746"},"language":"en","primary_location":{"id":"doi:10.33590/emjrheumatol/10311746","doi":"https://doi.org/10.33590/emjrheumatol/10311746","is_oa":true,"landing_page_url":"http://dx.doi.org/10.33590/emjrheumatol/10311746","pdf_url":"https://emjreviews.com/wp-content/uploads/sites/2/2018/07/Switching-to-Biosimilars-in-Inflammatory-Rheumatic-Conditions-Current-Knowledge.pdf","source":{"id":"https://openalex.org/S2736617174","display_name":"EMJ Rheumatology","issn_l":"2056-6395","issn":["2056-6395"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310311564","host_organization_name":"European Medical Journal","host_organization_lineage":["https://openalex.org/P4310311564"],"host_organization_lineage_names":["European Medical Journal"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"EMJ Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://emjreviews.com/wp-content/uploads/sites/2/2018/07/Switching-to-Biosimilars-in-Inflammatory-Rheumatic-Conditions-Current-Knowledge.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016081970","display_name":"Filipe Ara\u00fajo","orcid":"https://orcid.org/0000-0003-2711-0683","observed_orcids":["https://orcid.org/0000-0003-2711-0683"]},"institutions":[{"id":"https://openalex.org/I141596103","display_name":"University of Lisbon","ror":"https://ror.org/01c27hj86","country_code":"PT","type":"education","lineage":["https://openalex.org/I141596103"]},{"id":"https://openalex.org/I4405252715","display_name":"Hospital de Sant'Ana","ror":"https://ror.org/05d3apa77","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4405252715"]},{"id":"https://openalex.org/I4405257141","display_name":"Sociedade das Ci\u00eancias M\u00e9dicas de Lisboa","ror":"https://ror.org/04y5gfw04","country_code":"PT","type":"other","lineage":["https://openalex.org/I4405257141"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Filipe C. Ara\u00fajo","raw_affiliation_strings":["Rheumatology and Osteoporosis Unit, Hospital de Sant\u2019Ana, SCML, Portugal; Institute of Microbiology, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal",". Institute of Microbiology, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology and Osteoporosis Unit, Hospital de Sant\u2019Ana, SCML, Portugal; Institute of Microbiology, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal","institution_ids":["https://openalex.org/I141596103","https://openalex.org/I4405252715","https://openalex.org/I4405257141"]},{"raw_affiliation_string":". Institute of Microbiology, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal","institution_ids":["https://openalex.org/I141596103"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043747371","display_name":"Jo\u00e3o Eurico Fonseca","orcid":"https://orcid.org/0000-0003-1432-3671","observed_orcids":["https://orcid.org/0000-0003-1432-3671"]},"institutions":[{"id":"https://openalex.org/I141596103","display_name":"University of Lisbon","ror":"https://ror.org/01c27hj86","country_code":"PT","type":"education","lineage":["https://openalex.org/I141596103"]},{"id":"https://openalex.org/I4210149283","display_name":"Hospital de Santa Maria","ror":"https://ror.org/05bz1tw26","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210149283"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Joao Eurico Eurico Fonseca","raw_affiliation_strings":["Rheumatology Research Unit, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rheumatology Research Unit, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal","institution_ids":["https://openalex.org/I141596103","https://openalex.org/I4210149283"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074484305","display_name":"Jo\u00e3o Gon\u00e7alves","orcid":"https://orcid.org/0000-0002-1245-3715","observed_orcids":["https://orcid.org/0000-0002-1245-3715"]},"institutions":[{"id":"https://openalex.org/I141596103","display_name":"University of Lisbon","ror":"https://ror.org/01c27hj86","country_code":"PT","type":"education","lineage":["https://openalex.org/I141596103"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Joao Goncalves","raw_affiliation_strings":["Research Institute for Medicines (iMed), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Institute for Medicines (iMed), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal","institution_ids":["https://openalex.org/I141596103"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.5185,"has_fulltext":true,"cited_by_count":6,"citation_normalized_percentile":{"value":0.57471084,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":null,"issue":null,"first_page":"66","last_page":"74"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/biosimilars","display_name":"biosimilars","score":0.9739999771118164},{"id":"https://openalex.org/keywords/biosimilar-switching","display_name":"biosimilar switching","score":0.8799999952316284},{"id":"https://openalex.org/keywords/inflammatory-rheumatic-diseases","display_name":"inflammatory rheumatic diseases","score":0.9129999876022339},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8790000081062317},{"id":"https://openalex.org/keywords/interchangeability","display_name":"interchangeability","score":0.7749999761581421},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8199999928474426},{"id":"https://openalex.org/keywords/biosimilar-infliximab","display_name":"infliximab biosimilar","score":0.9729999899864197},{"id":"https://openalex.org/keywords/etanercept-biosimilar","display_name":"etanercept biosimilar","score":0.9369999766349792},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.7760000228881836},{"id":"https://openalex.org/keywords/health-care-expenditure","display_name":"health care expenditure","score":0.3720000088214874}],"concepts":[{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.9909766912460327},{"id":"https://openalex.org/C2779606619","wikidata":"https://www.wikidata.org/wiki/Q17092524","display_name":"Interchangeability","level":2,"score":0.8771976828575134},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7055217623710632},{"id":"https://openalex.org/C2781047461","wikidata":"https://www.wikidata.org/wiki/Q679692","display_name":"Biopharmaceutical","level":2,"score":0.4898986220359802},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.46473196148872375},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.4294441044330597},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.4291658103466034},{"id":"https://openalex.org/C2779962950","wikidata":"https://www.wikidata.org/wiki/Q5659376","display_name":"Harmonization","level":2,"score":0.4175112843513489},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.36469051241874695},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.34554556012153625},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3244861960411072},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.20198258757591248},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.18467140197753906},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.10819482803344727},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.08970871567726135},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C24890656","wikidata":"https://www.wikidata.org/wiki/Q82811","display_name":"Acoustics","level":1,"score":0.0},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.33590/emjrheumatol/10311746","doi":"https://doi.org/10.33590/emjrheumatol/10311746","is_oa":true,"landing_page_url":"http://dx.doi.org/10.33590/emjrheumatol/10311746","pdf_url":"https://emjreviews.com/wp-content/uploads/sites/2/2018/07/Switching-to-Biosimilars-in-Inflammatory-Rheumatic-Conditions-Current-Knowledge.pdf","source":{"id":"https://openalex.org/S2736617174","display_name":"EMJ Rheumatology","issn_l":"2056-6395","issn":["2056-6395"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310311564","host_organization_name":"European Medical Journal","host_organization_lineage":["https://openalex.org/P4310311564"],"host_organization_lineage_names":["European Medical Journal"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"EMJ Rheumatology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:ada74bf95e154a439452f81b954699c7","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/ada74bf95e154a439452f81b954699c7","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"European Medical Journal Rheumatology, Vol 5, Iss 1, Pp 66-74 (2018)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.33590/emjrheumatol/10311746","doi":"https://doi.org/10.33590/emjrheumatol/10311746","is_oa":true,"landing_page_url":"http://dx.doi.org/10.33590/emjrheumatol/10311746","pdf_url":"https://emjreviews.com/wp-content/uploads/sites/2/2018/07/Switching-to-Biosimilars-in-Inflammatory-Rheumatic-Conditions-Current-Knowledge.pdf","source":{"id":"https://openalex.org/S2736617174","display_name":"EMJ Rheumatology","issn_l":"2056-6395","issn":["2056-6395"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj"],"host_organization":"https://openalex.org/P4310311564","host_organization_name":"European Medical Journal","host_organization_lineage":["https://openalex.org/P4310311564"],"host_organization_lineage_names":["European Medical Journal"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"EMJ Rheumatology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8560000061988831}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4289776335.pdf","grobid_xml":"https://content.openalex.org/works/W4289776335.grobid-xml"},"referenced_works_count":49,"referenced_works":["https://openalex.org/W1855478184","https://openalex.org/W1954244899","https://openalex.org/W2022888597","https://openalex.org/W2067028313","https://openalex.org/W2098398245","https://openalex.org/W2121050884","https://openalex.org/W2148487286","https://openalex.org/W2151444904","https://openalex.org/W2161248953","https://openalex.org/W2162768160","https://openalex.org/W2203977709","https://openalex.org/W2288364750","https://openalex.org/W2293557195","https://openalex.org/W2296528535","https://openalex.org/W2342464058","https://openalex.org/W2345220764","https://openalex.org/W2403703304","https://openalex.org/W2480851940","https://openalex.org/W2543281533","https://openalex.org/W2549300825","https://openalex.org/W2551328509","https://openalex.org/W2555655461","https://openalex.org/W2589358629","https://openalex.org/W2594150134","https://openalex.org/W2595989365","https://openalex.org/W2610308940","https://openalex.org/W2613074462","https://openalex.org/W2623304866","https://openalex.org/W2669613733","https://openalex.org/W2735666560","https://openalex.org/W2764032337","https://openalex.org/W2766388803","https://openalex.org/W2767179430","https://openalex.org/W2775453485","https://openalex.org/W2790246629","https://openalex.org/W2791224008","https://openalex.org/W2793348928","https://openalex.org/W2793866077","https://openalex.org/W2794122890","https://openalex.org/W2794295970","https://openalex.org/W2796428896","https://openalex.org/W2801647441","https://openalex.org/W2886627072","https://openalex.org/W2954718837","https://openalex.org/W4247253112","https://openalex.org/W4251522057","https://openalex.org/W4253670512","https://openalex.org/W4254904072","https://openalex.org/W4256134701"],"related_works":["https://openalex.org/W2626689945","https://openalex.org/W4317193659","https://openalex.org/W6920721552","https://openalex.org/W2774189845","https://openalex.org/W3188094564","https://openalex.org/W2999614712","https://openalex.org/W4293171082","https://openalex.org/W2944087463","https://openalex.org/W2753037786","https://openalex.org/W3092350390"],"abstract_inverted_index":{"Biosimilars":[0],"are":[1,10,155,173,184],"more":[2],"affordable":[3],"versions":[4],"of":[5,44,77,93,101,132,134,214,233],"previously":[6],"approved":[7],"biopharmaceuticals":[8],"that":[9,222],"designed":[11],"to":[12,20,34,40,48,58,66,97,146,166,186,192,204,216,238],"reduce":[13],"healthcare":[14],"expenditure":[15],"and":[16,62,65,72,82,90,108,141,148,153,171,183,196,235],"increase":[17],"patient":[18],"access":[19],"this":[21,45,223],"therapeutic":[22],"class.":[23],"To":[24],"achieve":[25],"their":[26],"economic":[27],"potential,":[28],"many":[29],"European":[30,139,178,188],"countries":[31],"have":[32],"started":[33],"switch":[35,112],"patients":[36,234],"from":[37],"reference":[38],"drugs":[39],"biosimilars.":[41,116,167],"The":[42],"purpose":[43],"article":[46],"is":[47,211],"provide":[49],"a":[50,98,110,226],"comprehensive":[51],"perspective":[52],"on":[53,70,144,169],"the":[54,75,126,138,177,193,219,230,239],"biosimilar":[55],"switching":[56,63,71,87,145,165,170,215],"controversy,":[57],"assess":[59,205],"interchangeability":[60,172],"regulation":[61],"policies,":[64],"review":[67],"current":[68,142,209],"evidence":[69,143],"immunogenicity":[73,160],"in":[74,105,109,137,212],"context":[76],"inflammatory":[78],"rheumatic":[79],"conditions.":[80],"Patients":[81],"physicians":[83],"feel":[84],"uncertain":[85],"about":[86],"highly":[88],"complex":[89],"difficult-to-replicate":[91],"biosimilars":[92,122,133,150,217],"monoclonal":[94,135],"antibodies":[95,136],"due":[96],"theoretical":[99],"risk":[100],"increased":[102,159],"immunogenicity,":[103],"especially":[104],"extrapolated":[106],"indications":[107],"multiple":[111],"scenario":[113],"involving":[114],"various":[115],"However,":[117],"past":[118],"experience":[119],"with":[120,229],"smaller":[121],"(somatropin,":[123],"filgrastim,":[124],"epoetin),":[125],"high":[127],"standards":[128,203],"required":[129],"for":[130],"approval":[131],"market,":[140],"infliximab":[147],"etanercept":[149],"(especially":[151],"CT-P13":[152],"SB4)":[154],"reassuring.":[156],"Furthermore,":[157],"no":[158],"has":[161,201],"been":[162],"reported":[163],"after":[164],"Decisions":[168],"not":[174],"covered":[175],"by":[176],"Medical":[179],"Agency":[180],"(EMA)":[181],"guidelines":[182],"left":[185],"individual":[187],"states,":[189],"as":[190],"opposed":[191],"U.S.":[194],"Food":[195],"Drug":[197],"Administration":[198],"(FDA),":[199],"which":[200],"set":[202],"interchangeability.":[206],"In":[207],"summary,":[208],"knowledge":[210],"favour":[213],"but":[218],"authors":[220],"consider":[221],"should":[224],"be":[225],"physician-led":[227],"decision":[228],"active":[231],"contribution":[232],"hospital":[236],"pharmacists":[237],"pharmacovigilance":[240],"chain.":[241]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":4}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2022-08-04T00:00:00"}